Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk.
Thomsen went to boarding school in Epsom, Surrey in Great Britain from 1967 to 1971. He graduated from high school from Rungsted Statsskole in 1979. He holds a master's degree from The Royal Veterinary and Agricultural University in 1986, now part of the University of Copenhagen. According to Krogsgaard Thomsen himself, he originally wanted to be a practicing veterinarian, and was inspired by the British television series All Creatures Great And Small. At the Royal Veterinary and Agricultural University, however, he started to take an interest in pursuing a career in either science or the pharmaceutical industry. He finished his PhD. from the same university in 1989 and obtained the DSc. (Doctor of Science) degree within the pharmacology of experimental therapeutics in 1991.
Thomsen worked as a pharmacologist at Leo Pharma from 1989 to 1991 and was thereafter employed by Novo Nordisk in as head of Growth Hormone Research. He became senior vice president for diabetes R&D in 1994 and was appointed senior vice president of Health Care Discovery in 1995.
In November 2000, he was appointed executive vice president of Global R&D and chief scientific officer (CSO). As chief scientific officer, he was responsible for the research and development of 20 medicine products within diabetes, obesity and biopharmaceuticals. He led the development of GLP-1 therapies that today are among the leading treatments within type 2 diabetes and obesity. He left the position as executive vice president of R&D on February 28, 2021, and took the role as CEO of the Novo Nordisk Foundation on March 1, 2021.
He has been the president of the Danish Academy of Technical Sciences and has been on the board of directors at the Technical University of Denmark (DTU) and University of Copenhagen. From 2017 to 2020, Thomsen was the chairman of the board of directors at University of Copenhagen. Mads Krogsgaard Thomsen received the royal decoration of Knight of the Order of the Dannebrog by the Danish Royal House on 12 December 2022.
In 2024, Thomsen received the Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer.
Thomsen joined Novo Nordisk in 1991 as the head of growth hormone research. In 1994, he was appointed senior vice president of diabetes research & development. In November 2000, he became executive vice president and chief scientific officer, overseeing global operations related to drug and device research, chemistry, manufacturing and controls (CMC), global development, medical affairs, regulatory affairs, and safety. During his tenure, more than 20 pharmaceutical products were developed and approved.
During his tenure as chief scientific officer at Novo Nordisk, Thomsen played a significant role in the development of GLP-1-based therapies, including Ozempic and Wegovy. In the early 1990s, despite skepticism from company leadership regarding the potential of obesity treatments, Thomsen advocated for focusing on obesity as a significant health issue. This strategic direction led to the development of Ozempic, approved for Type 2 diabetes treatment in 2017, and Wegovy, approved for weight loss in 2021. Both medications are based on semaglutide, a GLP-1 receptor agonist designed to regulate blood sugar levels and appetite.
On March 1, 2021, Thomsen was appointed CEO of the Novo Nordisk Foundation, a philanthropic organization that funds research in health, life sciences, and sustainability.
Thomsen has been an adjunct professor at the Royal Veterinary and Agricultural University (now the Faculty of Health and Medical Sciences at the University of Copenhagen) since 2000. He has also served on the editorial boards of various international peer-reviewed journals and has published extensively in the fields of pharmacology, immunology, endocrinology, and haemostasis.
List of publications associated to Mads Krogsgaard Thomsen:
Thomsen has been recognized for his contributions to pharmaceutical research and development. His work has supported advancements in drug discovery and innovation in medical science.
Thomsen has held several leadership and advisory positions in academia and industry. Additionally, he has served as chairman of the Danish Biotech Research and Innovation Centre and has participated in governmental committees related to post-graduate education reforms in Denmark.
Thomsen is married to Ulla. He has three children from previous marriages.